CELA3A: A Potential Drug Target and Biomarker (G10136)
CELA3A: A Potential Drug Target and Biomarker
CELA3A is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. Its full name is CELA3A, and it is a member of the Calbindin family of proteins. Calbindin is a widely expressed protein that is involved in a variety of cellular processes, including cell signaling, cytoskeletal organization, and neurotransmitter release. CELA3A, with its unique expression pattern and function, has been identified as a potential drug target and biomarker.
The CELA3A protein is expressed in the brain and other tissues, and its levels have been shown to be elevated in individuals with various neurological disorders, such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis. Additionally, CELA3A has been shown to be involved in neurotransmitter release, which is critical for the function of neurons and the development of neurotransmitter-related disorders.
CELA3A has also been shown to play a role in the regulation of pain perception and neuroinflammation. Chronic pain is a prevalent condition that can have a significant impact on an individual's quality of life, and research has suggested that CELA3A may be involved in the development and treatment of chronic pain.
In addition to its potential role in neurological disorders, CELA3A has also been shown to be involved in the development and progression of certain diseases. For example, CELA3A has been shown to be expressed in the lungs of individuals with chronic obstructive pulmonary disease (COPD), and increased levels of CELA3A have been associated with the development of COPD in animal models. Similarly, CELA3A has been shown to be involved in the development and progression of cancer, with increased levels of CELA3A being observed in various types of cancer.
Despite its potential as a drug target and biomarker, much more research is needed to fully understand the role of CELA3A in various biological processes. For example, it is unclear whether modulating CELA3A levels or activity can be a effective way to treat neurological disorders or diseases. Additionally, the development of CELA3A-targeted therapies may also have potential ethical implications, as the use of certain drugs that target this protein may raise concerns about potential harm to individuals.
In conclusion, CELA3A is a protein that has been identified as a potential drug target and biomarker. Its unique expression pattern and function in various tissues make it an attractive target for further research, with the potential to contribute to the development of new treatments for a variety of neurological disorders and diseases.
Protein Name: Chymotrypsin Like Elastase 3A
Functions: Efficient protease with alanine specificity but only little elastolytic activity
More Common Targets
CELA3B | CELF1 | CELF2 | CELF2-AS1 | CELF2-AS2 | CELF3 | CELF4 | CELF5 | CELF6 | CELP | CELSR1 | CELSR2 | CELSR3 | CEMIP | CEMIP2 | CEMP1 | CENATAC | CEND1 | CENP-A-nucleosome distal (CAD) centromere complex | CENPA | CENPA-CAD (nucleosome distal) complex | CENPA-NAC (nucleosome-associated) complex | CENPB | CENPBD1P | CENPBD2P | CENPC | CENPCP1 | CENPE | CENPF | CENPH | CENPI | CENPIP1 | CENPJ | CENPK | CENPL | CENPM | CENPN | CENPO | CENPP | CENPQ | CENPS | CENPS-CORT | CENPT | CENPU | CENPV | CENPVL1 | CENPW | CENPX | Centralspindlin complex | CEP104 | CEP112 | CEP120 | CEP126 | CEP128 | CEP131 | CEP135 | CEP152 | CEP162 | CEP164 | CEP170 | CEP170B | CEP170P1 | CEP19 | CEP192 | CEP20 | CEP250 | CEP290 | CEP295 | CEP295NL | CEP350 | CEP350-FGFR1OP-MAPRE1 complex | CEP41 | CEP43 | CEP44 | CEP55 | CEP57 | CEP57L1 | CEP63 | CEP68 | CEP70 | CEP72 | CEP72-DT | CEP76 | CEP78 | CEP83 | CEP83-DT | CEP85 | CEP85L | CEP89 | CEP95 | CEP97 | CEPT1 | CER1 | Ceramidase | Ceramide synthase | CERCAM | CERK | CERKL | CERNA2 | CERS1